Paclitaxel is approved by the U.S. Food and Drug Administration (FDA) for use against breast cancer, non-small cell lung cancer, ovarian cancer, AIDS-related Kaposi’s sarcoma and pancreatic cancer.
Doctors also use it as an experimental or off-label treatment for bladder cancer, esophageal cancer, melanoma, prostate cancer and mesothelioma. Paclitaxel is commonly given in combination with cisplatin or carboplatin.
Paclitaxel is an antimicrotubule agent. Microtubules are an essential part of the process by which cells divide. Paclitaxel binds to proteins in cell microtubules, which forces cells to stop dividing. Since cancer cells divide rapidly, their microtubules are a good target for chemotherapy.
This drug dates back to the late 1960s, when it was discovered in the bark of the Pacific yew tree. Researchers recognized its potential as an anti-cancer agent, but its natural scarcity made it difficult to market.
More than 20 years later, researchers found a way to produce paclitaxel synthetically. Bristol-Myers Squibb began marketing it as Taxol.
In 2005, the FDA approved a new type of the drug called nanoparticle albumin-bound paclitaxel, or nab-paclitaxel. In this formulation, the drug is contained in tiny particles of protein. This improves drug delivery and reduces side effects. Celgene Corporation markets nab-paclitaxel as Abraxane.
|Manufacturer||Bristol-Myers Squibb, Celgene|
|Administration Route||Intravenous or intraperitoneal|
|Drug Class||Antineoplastic agent, antimicrotubule agent|
|Alternate Names||Anzatax, Asotax, Bristaxol, Onxol, Praxel|
|Interacting Drug||Adenovirus types 4 and 7 live, antihistamines, apalutamide, eluxadoline, idarubicin, idelalisib, influenza virus vaccine trivalent, ivacaftor, nefazodone, opiates, palifermin, quinidine|
|Medical Studies||Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival|
|FDA Warning||Skin problems, hives, acute allergic reaction characterized by breathing difficulty and low blood pressure|
Learn About COVID-19 and Mesothelioma
Get a free recording of the COVID-19 and mesothelioma presentation hosted by the experts at The Mesothelioma Center.Get Yours Now
Paclitaxel for Pleural Mesothelioma
In the 1990s, studies of paclitaxel (Taxol) as a single agent for pleural mesothelioma showed little effectiveness. Now researchers are testing nab-paclitaxel (Abraxane) in combination with other drugs.
A 2016 study published in Respirology Case Reports described one medical team’s success substituting nab-paclitaxel for pemetrexed.
Standard chemotherapy for mesothelioma combines pemetrexed with cisplatin or carboplatin, but pemetrexed is too toxic for some patients. In the case report, a pleural mesothelioma patient responded well to nab-paclitaxel with carboplatin after standard chemotherapy had failed.
In 2017, Clinical Cancer Research published the results of a laboratory experiment using mesothelioma cells. The researchers combined nab-paclitaxel with an experimental immunotoxin called RG7787, with good results.
That same year, Biomedicine & Pharmacotherapy reported on a novel drug delivery method for mesothelioma. The laboratory experiment involved loading paclitaxel into a special type of cell to help the drug reach cancer cells.
Paclitaxel for Peritoneal Mesothelioma
Paclitaxel also shows promise for peritoneal mesothelioma, according to a 2017 review in the European Journal of Surgical Oncology. The review was co-authored by Dr. Paul Sugarbaker.
Sugarbaker helped pioneer the technique of rinsing a patient’s abdomen with chemotherapy during surgery. This procedure is called hyperthermic intraperitoneal chemotherapy (HIPEC). It is associated with much longer survival times for peritoneal mesothelioma patients.
In the 2017 review, Sugarbaker’s team reported that outcomes are the best for patients who also get long-term paclitaxel. In these follow-up treatments, the drug is delivered to their abdomen to prevent cancer reoccurrence.
Side Effects of Paclitaxel
Like most chemotherapy drugs, paclitaxel damages healthy cells in addition to cancer cells. Side effects are usually worst about 15 to 21 days after treatment.
Common side effects of paclitaxel:
- Low red- and white-blood-cell counts
- Hair loss
- Joint and muscle pain
- Numbness and tingling in extremities
- Nausea and vomiting
- Mouth sores
- Severe allergic reaction
Rare side effects of paclitaxel:
- Swelling in feet or ankles
- Liver problems
- Low blood pressure
- Skin darkening at radiation treatment sites
- Nail discoloration
11 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
U.S. National Library of Medicine. (2017, November 4). Paclitaxel.
Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/paclitaxel#section=Top
Sugarbaker, P. and Chang, D. (2017, July). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28189456
Petrella, F. et al. (2017, March). Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28153512
Zhang, J. et al. (2017, March). Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/27635089
Kanai, O. et al. (2016, January). Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
Retrieved from: http://onlinelibrary.wiley.com/doi/10.1002/rcr2.145/pdf
National Cancer Institute. (2014, September 18). Paclitaxel.
Retrieved from: https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel
MedlinePlus. (2011, February 1). Paclitaxel Injection. #
Retrieved from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607070.html
Stephenson, F. (2002). A Tale of Taxol.
Retrieved from: http://www.rinr.fsu.edu/fall2002/taxol.html
Vogelzang, N. et al. (1999). High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/10416012
Van Meerbeeck, J. et al. (1996). Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/pdf/brjcancer00022-0129.pdf
- Chemocare. (n.d.). Paclitaxel. Retrieved from: http://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified April 12, 2020